1971-LB: Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD—Data from the FLOW Trial

Le résumé fourni par la source

Introduction and Objective: In FLOW, semaglutide reduced the risk of kidney, cardiovascular (CV), and mortality outcomes in people with type 2 diabetes (T2D) and chronic kidney disease (CKD). We now test how the benefit of semaglutide relates to baseline BMI and change in body weight (BW). Methods: Participants were randomized to once-weekly subcutaneous semaglutide 1.0 mg or placebo (N= 3,533). The primary kidney outcome was a composite of kidney failure, sustained estimated glomerular filtration rate reduction of ≥50%, or kidney or CV death. Key secondary outcomes included major adverse CV events and all-cause death. Subgroup analyses by BMI used a Cox proportional hazards model; mediation analyses by change in BW used a repeated regression approach. Results: Mean baseline BMI and BW were 32.0 kg/m2 and 89.6 kg, respectively. The effect of semaglutide on the primary kidney outcome, major adverse CV events, and all-cause death was consistent across baseline BMI categories (interaction p value range, 0.6217 to 0.9471) (Figure). The estimated percentage mediation (95% CI) of BW loss was -0.5% (-29.8, 37.8) on the primary kidney outcome; -33.4% (-273.1, 82.0) for major adverse CV events; and -25.6% (-150.5, 34.3) for all-cause death. Conclusion: Semaglutide benefits on kidney, CV, and mortality outcomes were independent of baseline BMI, and did not seem to be explained by change in BW. Disclosure J.F.E. Mann: Other Relationship; AstraZeneca, Bayer Pharmaceuticals, Inc. Advisory Panel; Novo Nordisk. Board Member; AstraZeneca, Bayer Pharmaceuticals, Inc, Boehringer-Ingelheim, Novo Nordisk. Other Relationship; Sanofi. Consultant; AstraZeneca, Bayer Pharmaceuticals, Inc, Novo Nordisk. Research Support; AstraZeneca. Other Relationship; Boehringer-Ingelheim. Research Support; Novo Nordisk, Sanofi. Speaker's Bureau; AstraZeneca, Bayer Pharmaceuticals, Inc, Novo Nordisk, Novartis AG. Other Relationship; UpToDate Inc / KDIGO. K.R. Tuttle: Consultant; Lilly Diabetes, Boehringer-Ingelheim, Novo Nordisk, Pfizer Inc. Other Relationship; AstraZeneca. Consultant; Bayer Pharmaceuticals, Inc, Traveere Pharmaceuticals, ProKidney. R.E. Pratley: Consultant; AbbVie Inc. Stock/Shareholder; Altanine, Inc. Consultant; Amgen Inc, AstraZeneca. Other Relationship; Bayer AG, Bayer Pharmaceuticals, Inc, Biomea Fusion. Consultant; Boehringer-Ingelheim. Other Relationship; Carmot Therapeutics, Inc, Corcept Therapeutics, Dompé, Eli Lilly and Company, Endogenex. Consultant; Endogenex. Other Relationship; Fractyl Health, Inc., Gasherbrum Bio, Inc. Consultant; Genprex, Getz Pharma, Hanmi Pharm. Co., Ltd, Intas Pharmaceuticals Ltd, Lexicon Pharmaceuticals, Inc, Lilly USA LLC. Speaker's Bureau; Lilly USA LLC. Other Relationship; Metavention, Novo Nordisk, Novo Nordisk. Speaker's Bureau; Novo Nordisk. Other Relationship; Pfizer Inc, Poxel SA. Consultant; Regeneron Pharmaceuticals. Other Relationship; Sanofi. Consultant; Scholar Rock. Other Relationship; Sun Pharmaceutical Industries Ltd. K.W. Mahaffey: Research Support; American College of Cardiology, American Heart Association. Consultant; Applied Therapeutics. Research Support; Apple, Inc. Other Relationship; Bayer Pharmaceuticals, Inc. Consultant; Bristol-Myers Squibb Company, BridgeBio. Research Support; California Institute Regenerative Medicine, CSL Behring, Cytokinetics Inc, Eidos, Element. Consultant; Eli Lilly and Company, Elsevier. Research Support; Ferring. Consultant; Fosun Pharma. Research Support; Gilead Sciences, Inc, Google (Verily). Other Relationship; Human. Research Support; Idorsia. Other Relationship; Johnson & Johnson. Research Support; Luitpold. Stock/Shareholder; Medeloop (I have equity in this company). Consultant; Moderna, Inc, Myokardia. Research Support; Myovant. Other Relationship; Novartis. Consultant; Novo Nordisk. Research Support; PAC-12. Consultant; PhaseBio Pharmaceuticals, Inc, Portola. Other Relationship; Precordior. Consultant; Quidel. Stock/Shareholder; Regencor (I have equity in this company). Research Support; Sanifit. Consultant; Scleroderma Foundation. Research Support; St Jude Medical. Consultant; Theravance. M. Arici: Speaker's Bureau; Amgen Inc. Advisory Panel; Astellas Pharma Inc, AstraZeneca. Speaker's Bureau; Bayer Pharmaceuticals, Inc, Boehringer-Ingelheim, Menarini. Research Support; Novo Nordisk. Speaker's Bureau; Sanofi. Other Relationship; CSL Behring. N. Belmar: Employee; Novo Nordisk A/S. K. Bonefeld: Employee; Novo Nordisk A/S. G. Chernin: None. R. Correa-Rotter: Other Relationship; AstraZeneca, Bayer Pharmaceuticals, Inc, Novo Nordisk. Research Support; Roche Pharmaceuticals. Other Relationship; Boehringer-Ingelheim. Speaker's Bureau; Amgen Inc. Research Support; Lilly USA LLC. Speaker's Bureau; Sanofi. P. Gillard: Research Support; Novo Nordisk A/S, Sanofi, Dexcom, Inc., Tandem Diabetes Care, Inc, Medtronic. Speaker's Bureau; Abbott, Bayer Pharmaceuticals, Inc. Advisory Panel; Ypsomed AG. Speaker's Bureau; Air Liquide. Research Support; Roche Diabetes Care. S. Hadjadj: Consultant; AstraZeneca. Other Relationship; Boehringer-Ingelheim. Speaker's Bureau; Eli Lilly and Company. Research Support; Novartis AG. Consultant; Novo Nordisk. Other Relationship; Sanofi. Advisory Panel; Valbiotis. T. Idorn: Employee; Novo Nordisk A/S. L. Ji: None. M. Linder: Employee; Novo Nordisk A/S. R.E. Schmieder: Research Support; Bayer Pharmaceuticals, Inc. Speaker's Bureau; Boehringer-Ingelheim. Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. M. Shamkhalova: None. A. Sriwijitkamol: None. V. Perkovic: Other Relationship; AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, GlaxoSmithKline, HiBio, Janssen, Novo Nordisk, Novartis, Otsuka, Travere, Tricida, UpToDate. Board Member; St Vincents Health Australia, Mindgardens Neuroscience Network, Kidney Health Australia. Stock/Shareholder; George Clinical. P. Rossing: Speaker's Bureau; Abbott. Advisory Panel; AstraZeneca, Bayer Pharmaceuticals, Inc, Boehringer-Ingelheim, Gilead Sciences, Inc, Novo Nordisk. Other Relationship; Lexicon Pharmaceuticals, Inc. Speaker's Bureau; Daiichi Sankyo.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.